Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
| Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
| Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
| Jetrea | Ocriplasmin | Vitreomacular adhesion | List with criteria/condition | Complete | ||
| Actemra | Tocilizumab | Arthritis, polyarticular juvenile idiopathic | List with criteria/condition | Complete | ||
| Tudorza Genuair | Aclidinium bromide | Chronic Obstructive Pulmonary Disease | List with criteria/condition | Complete | ||
| Galexos | Simeprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | ||
| Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete | ||
| Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete |
Last Updated : May 17, 2024